Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium

Description

This study will assess the use of autologous bone marrow stem cells mobilization using 1,1'-\[1,4-phenylenebis-(methylene)\]-bis-1,4,8,11-tetraazacyclotetradecane (PLERIXAFOR) as an effective medical therapy for the treatment of Asherman's Syndrome (AS), Atrophic Endometrium (AE) and Recurrent Implantation Failure (RIF).

Conditions

Asherman Syndrome, Atrophic Endometrium, Recurrent Implantation Failure

Talk to us

Study Overview

On this page

Study Details

Study overview

This study will assess the use of autologous bone marrow stem cells mobilization using 1,1'-\[1,4-phenylenebis-(methylene)\]-bis-1,4,8,11-tetraazacyclotetradecane (PLERIXAFOR) as an effective medical therapy for the treatment of Asherman's Syndrome (AS), Atrophic Endometrium (AE) and Recurrent Implantation Failure (RIF).

Bone Marrow Derived Stem Cells Mobilization for Treatment of Asherman's Syndrome, Atrophic Endometrium, and Recurrent Implantation Failure

Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium

Condition
Asherman Syndrome
Intervention / Treatment

-

Contacts and Locations

Orange

Yale Fertility Center, Orange, Connecticut, United States, 06477

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Healthy, non pregnant females
  • * ages ≥18 and ≤40 years old at time of enrollment
  • * with either AS, AE, or RIF
  • 1. For AS: surgical history of intrauterine trauma/infection, hypo/amenorrhea, intra-uterine adhesions
  • 2. for AE: US documentation of persistent, \<6mm endometrial thickness
  • 3. for RIF: failure to achieve a clinical pregnancy after transfer of at least four good-quality embryos in a minimum of three fresh or frozen cycles in a woman under 40 years and currently being treated at Yale Fertility Clinic
  • * Presence of hydrosalpinx (diagnosed by radiographic or ultrasound imaging)
  • * Endometriosis (diagnosed by previous surgery,)
  • * Diminished ovarian reserve (AMH\<1ng/ml or follicle stimulating hormone (FSH)\>10)
  • * History of genital tuberculosis or any ultrasound evidence of congenital uterine anomaly
  • * Submucous or intracavitary fibroid, polyps
  • * Currently pregnant
  • * Personal history of thrombophilia or sickle cell disease
  • * Inability to provide informed consent

Ages Eligible for Study

18 Years to 40 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Hugh Taylor,

Hugh Taylor, MD, PRINCIPAL_INVESTIGATOR, Yale University

Study Record Dates

2026-12